Managing Director & Founder
PhD, MBA, MAICD
Dr Ian Dixon has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications.
Ian has been successful in translating technology challenges into valuable businesses and respected intellectual property.
Ian is a co-inventor of Exopharm’s LEAP manufacturing technology and a co-inventor of Fortrexo, part of Exopharm’s EEV pipeline.
Ian brings to Exopharm an extensive technical, commercial and entrepreneurial background.
Before founding Exopharm in 2013, Ian co-founded Cynata Inc, the owner of the Cymerus stem cell technology now being commercialised by ASX-listed clinical-stage Cynata Therapeutics Ltd (ASX:CYP).
He is also non-executive director of NYRADA Inc. (ASX:NYR), co-inventor of Nyrada PCSK9 inhibitor drug NYX-330, and founder and investor of Cardio Therapeutics Pty Ltd.
Ian was previously a founding director of Sydney-based Noxopharm Ltd (ASX:NOX) and non-executive director of Melbourne unlisted company Cell Therapies Pty Ltd.
Chief Technology Officer
Mike holds a PhD in Chemistry and graduate qualifications in law and management. He brings 23 years of industry experience in drug development of both pre-clinical and clinical assets. Mike has worked in big-Pharma and has had C-suite roles in several biotechnology companies, bringing a wealth of experience in technology management to Exopharm.
Mike will drive technology and drug development at Exopharm, to reinforce our world leading reputation. Mike is also assisting in the selection of the pipeline products and will contribute to the development programs of those products.